What is Santhera Pharmaceuticals Holding AG Current Ratio?
Santhera Pharmaceuticals Holding AGSPHDF 39 Current Ratio is 1.29 as of Dec. 2025, which is 12% below its 10-year median of 1.47. GuruFocus rates SPHDF with a GF Score™ of 39/100 and a GF Value™ of $24.73 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,417 Biotechnology companies, Santhera Pharmaceuticals Holding AG ranks worse than 79.68% on this metric.
SPHDF'
s Current Ratio Range Over the Past 10 Years
Min: 0.06 Med: 1.47 Max: 6.08
Current: 1.29
During the past 13 years, Santhera Pharmaceuticals Holding AG's highest Current Ratio was 6.08. The lowest was 0.06. And the median was 1.47.
SPHDF's Current Ratio is ranked worse than 79.68% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs SPHDF: 1.29
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Santhera Pharmaceuticals Holding AG Current Ratio Related Terms
Santhera Pharmaceuticals Holding AG Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG Current Ratio Chart
SPHDF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (SPHDF) has a Current Ratio of 1.29 as of Dec. 2025. This is 12% below median its historical median of 1.47. Over the past decade, Santhera Pharmaceuticals Holding AG's Current Ratio has ranged from 0.06 to 6.08. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #1129 out of 1417 companies in the Biotechnology industry, placing it in the top 79.7%.
Is Santhera Pharmaceuticals Holding AG's Current Ratio too high?
Santhera Pharmaceuticals Holding AG's current Current Ratio of 1.29 is 12% below median its 10-year median of 1.47. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 6.08. The Biotechnology industry median Current Ratio is 3.89. Santhera Pharmaceuticals Holding AG's value of 1.29 is 66.8% below this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #1129 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #1129 out of 1417 companies for Current Ratio. This places Santhera Pharmaceuticals Holding AG in the lower half of its industry. The industry median Current Ratio is 3.89. Santhera Pharmaceuticals Holding AG's value of 1.29 is 66.8% below this benchmark. Historically, Santhera Pharmaceuticals Holding AG's own Current Ratio has ranged from 0.06 to 6.08 over the past decade. While the company's 10-year median is 1.47 vs. the industry median of 3.89, Santhera Pharmaceuticals Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Current Ratio of 1.29 is 66.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Current Ratio is 1.29, which is 12% below median its own 10-year median of 1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (SPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $24.73, compared to a current price of $23.25 — trading 6% below its estimated fair value. The current Current Ratio is 1.29, which is 12% below median its 10-year median of 1.47 and 66.8% below the Biotechnology industry median of 3.89. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current Current Ratio is 1.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.
Key valuation signals for SPHDF:
Current Ratio: 1.29 (12% below median its 10-year median of 1.47)
GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
Industry Position: 66.8% below the Biotechnology median (#1129 of 1417)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for SPHDF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
